impact factor
logo
 

Full Papers

 

User experience with a voice-enabled smartphone app to collect patient-reported outcomes in rheumatoid arthritis


1, 2, 3, 4, 5, 6, 7, 8, 9, 10

 

  1. Brigham and Women's Hospital, Boston, MA, USA.
  2. Brigham and Women's Hospital, Boston, MA, USA.
  3. Brigham and Women's Hospital, Boston, MA, USA.
  4. Brigham and Women's Hospital, Boston, MA, USA.
  5. ADK Group, Boston, MA, USA.
  6. ADK Group, Boston, MA, USA.
  7. Janssen Research and Development, NJ, USA.
  8. Janssen Research and Development, NJ, USA.
  9. Brigham and Women's Hospital, Boston, MA, USA.
  10. Brigham and Women's Hospital, Boston, MA, USA. dsolomon@bwh.harvard.edu

CER14339
2022 Vol.40, N°5
PI 0882, PF 0889
Full Papers

purchase article

PMID: 35200118 [PubMed]

Received: 17/12/2020
Accepted : 13/04/2021
In Press: 01/02/2022
Published: 11/05/2022

Abstract

OBJECTIVES:
Rheumatoid arthritis (RA) is a chronic disease, requiring frequent patient-provider interaction and self-monitoring. We developed a novel mobile health smartphone app with a voice-enabled feature to help patients virtually track disease activity and ask general questions about RA.
METHODS:
With a user-centered design (UCD) approach, we developed a voice-enabled app (VEA) which was then tested in two focus groups of patients (n=8) and one with providers (n=4). Voice enablement and a question and answer (Q & A) library function were previously requested by patients. Based on focus group feedback, the VEA was refined and tested with 26 patients for 56 days. The VEA asked patients to fill in daily patient-reported outcomes (PROs) and complete the trial with a satisfaction survey.
RESULTS:
Of the 26 patients in the VEA trial, 77% were female and 50% were aged 55 and older. Adherence to daily PROs during the 56-day trial was 66%, with <1% of PROs completed using the voice-enabled feature. PROMIS short forms and RADAI-5 PROs remained stable. Of the 22 satisfaction survey respondents, 86% were satisfied with their overall experience with the app and 18.5% were satisfied with voice enablement. The voice assistant had an 86% success rate at understanding and answering interactions regarding surveys and a 44% success rate regarding Q & A interactions.
CONCLUSIONS:
We developed a novel VEA through a UCD framework and conducted pilot testing. Adherence was moderate and RADAI-5 and PROMIS measures were stable. Based on satisfaction results, PROs may not be the best use of voice enablement technology.

DOI: https://doi.org/10.55563/clinexprheumatol/xsdfl2

Rheumatology Article

Rheumatology Addendum